期刊文献+

Peaking of MMP-26 and TIMP-4 marks invasive transition in prostate cancer 被引量:1

Peaking of MMP-26 and TIMP-4 marks invasive transition in prostate cancer
下载PDF
导出
摘要 Prostate cancer is one of the leading health threats to man,and like many other cancers,early detection and treatment iscrucial to improving the prognosis of patients.Progression of the disease from noninvasive high-grade prostatic intraepi-thelial neoplasia (HGPIN) to invasive adenocarcinoma is linked to the action of a group of proteolytic enzymes calledmatrix metalloproteinases (MMPs),which digest various components of the extracellular matrix and thus open waysfor tumor metastasis.Previous studies have shown that one MMP,MMP-26,is expressed at a significantly higher levelin human prostate carcinoma than in normal prostate tissues,and that it appears to play an important role in promotinginvasion of prostate cancer cells [1].In this issue of Cell Research,Lee et al.report detailed analyses of the expressionpattern of MMP-26,along with its most potent endogenous inhibitor,TIMP-4 (TIMP stands for tissue inhibitor ofmetal-loproteinases),in a number of prostate cancer samples derived from human patients [2].Interestingly,they found Prostate cancer is one of the leading health threats to man, and like many other cancers, early detection and treatment is crucial to improving the prognosis of patients. Progression of the disease from noninvasive high-grade prostatic intraepithelial neoplasia (HGPIN) to invasive adenocarcinoma is linked to the action of a group of proteolytic enzymes called matrix metalloproteinases (MMPs), which digest various components of the extracellular matrix and thus open ways for tumor metastasis. Previous studies have shown that one MMP, MMP-26, is expressed at a significantly higher level in human prostate carcinoma than in normal prostate tissues, and that it appears to play an important role in promoting invasion of prostate cancer cells [1 ]. In this issue of Cell Research, Lee et al. report detailed analyses of the expression pattern of MMP-26, along with its most potent endogenous inhibitor, TIMP-4 (TIMP stands for tissue inhibitor of metalloproteinases), in a number of prostate cancer samples derived from human patients [2]. Interestingly, they found that both MMP-26 and TIMP-4 exhibit the highest expression in HGPIN; and the levels of both proteins are significantly lower in adjacent cancer areas in the same tissues [2]. Consistent with earlier results, the lowest expression of MMP-26 (and TIMP-4) was found in non-neoplastic tissues. As HGPIN is considered the preinvasive precursor form of prostate cancer, the study by Lee et al. implicates that the expression of MMP-26 and TIMP-4 is coordinately regulated during disease progression. This finding is reminiscent of the authors' earlier study in breast cancer, where they showed that the expression of MMP-26 and TIMP-4 is significantly higher in preinvasive ductal carcinoma in situ comparing to invasive ductal carcinoma, hyperplasia, and normal breast epithelia [3]. While the functional significance of the apparently coordinated expression pattern of MMP-26 and TIMP-4 during malignant transition remains to be deciphered, these results suggest that peak expression of MMP-26 and TIMP-4 may underlie the conversion from noninvasive to invasive growth by the tumors. Moreover, the highest expression of these factors in HGPIN raises the possibility that they could be used as new biomarkers for early diagnosis of a subset of prostate cancer patients before metastasis.
作者 Dangsheng Li
机构地区 Cell Research
出处 《Cell Research》 SCIE CAS CSCD 2006年第9期741-741,共1页 细胞研究(英文版)
  • 相关文献

参考文献1

二级参考文献30

  • 1Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18:1135-1149.
  • 2Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463-516.
  • 3Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:163-176.
  • 4Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 1999; 19:1589-1592.
  • 5Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999; 103:1237-1241.
  • 6Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270.
  • 7Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity.Cancer Res 2000; 60:4745-4751.
  • 8Park HI, Ni J, Gerkema FE, et al. Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem 2000; 275:20540-20544.
  • 9de Coignac AB, Elson G, Delneste Y, et al. Cloning of MMP-26. A novel matrilysin-like proteinase. Eur J Biochem 2000;267:3323-3329.
  • 10Marchenko GN, Ratnikov BI, Rozanov DV, et al. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J 2001 : 356:705-718

共引文献17

同被引文献6

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部